Lisa Johnson

6PUBLICATIONS
42CO-AUTHORS
Regenerative medicine (incl. stem cells)Medical biotechnology not elsewhere classifiedGene and molecular therapyApplied immunology (incl. antibody engineering, xenotransplantation and t-cell therapies)Molecular targets
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (6)

|Jul 13, 2026
Magrolimab Plus Azacitidine Versus Placebo Plus Azacitidine in Patients With Untreated Higher-Risk Myelodysplastic Syndromes: The Phase III ENHANCE Study.

|Apr 15, 2025
The ENHANCE-3 study: venetoclax and azacitidine plus magrolimab or placebo for untreated AML unfit for intensive therapy.

Naval Daver, Paresh Vyas, Gerwin Huls

|Feb 26, 2025
Magrolimab plus azacitidine vs physician's choice for untreated TP53-mutated acute myeloid leukemia: the ENHANCE-2 study.

Joshua F Zeidner, David A Sallman, Christian Récher

|Nov 16, 2023
Transfusion management in the era of magrolimab (Hu5F9-G4), an anti-CD47 monoclonal antibody therapy.

Nirupama Singh, Julie Staves, Jill R Storry

|Jan 16, 2021
Phase I Study of the CD47 Blocker TTI-621 in Patients with Relapsed or Refractory Hematologic Malignancies.

Stephen M Ansell, Michael B Maris, Alexander M Lesokhin

|Apr 10, 2019
Targeting CD47 in Sézary syndrome with SIRPαFc.

Lisa D S Johnson, Swati Banerjee, Oleg Kruglov

Pageof 1

Frequent Collaborators

3 joint publications

Paresh Vyas

3 joint publications

Naval G Daver

2 joint publications

Oleg E Akilov

2 joint publications

Pau Montesinos